Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03399773
Other study ID # 9910
Secondary ID NCI-2017-0220599
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 10, 2022
Est. completion date June 30, 2026

Study information

Verified date February 2024
Source Fred Hutchinson Cancer Center
Contact Filippo Milano
Phone 206.667.5925
Email fmilano@fredhutch.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial studies how well donor umbilical cord blood transplant with ex-vivo expanded cord blood progenitor cells (dilanubicel) works in treating patients with blood cancer. Before the transplant, patients will receive chemotherapy (fludarabine, cyclophosphamide and in some cases thiotepa) and radiation therapy. Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells.


Description:

OUTLINE: Patients receive either regimen A or regimen B. REGIMEN A: Patients (10 through 45 years old) receive fludarabine intravenously (IV) over 30 minutes on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo total body irradiation (TBI) twice daily (BID) on days -4 to -1. Patients receive unmanipulated cord blood unit IV followed by dilanubicel IV within the next 24 hours on day 0. REGIMEN B: Patients (10 through 65 years old) receive fludarabine IV over 30-60 minutes on days -6 to -3 and IV over 30 minutes on day -2, cyclophosphamide IV on day -6, and thiotepa IV over 2-4 hours on days -5 and -4. Patients undergo TBI once daily (QD) on days -2 and -1. Patients receive unmanipulated cord blood unit IV followed by dilanubicel IV within the next 24 hours on day 0. All patients undergo bone marrow aspirate and biopsy as clinically indicated during screening and on study. Patients undergo multigated acquisition scan (MUGA) or echocardiography (ECHO), and computed tomography (CT) during screening. Patients also undergo blood sample collection on study. After completion of study treatment, patients are followed up at 180 days, 1 year, and 2 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date June 30, 2026
Est. primary completion date October 8, 2024
Accepts healthy volunteers No
Gender All
Age group 10 Years to 65 Years
Eligibility Inclusion Criteria: - Patients 10 to 65 years old with a hematologic malignancy in need of hematopoietic cell transplant who are > 30 kg and without a suitable related donor - Patient must have hematologic malignancy that meets institutional eligibility requirements for cord blood transplant - Malignancies included are: - Acute leukemia, including acute myeloid leukemia (AML), biphenotypic acute leukemia or mixed-lineage leukemia, acute lymphoblastic leukemia (ALL); all patients must be in complete response (CR) as defined by < 5% blasts by morphology/flow cytometry in a representative bone marrow sample with adequate cellularity to assess remission status - Myelodysplasia (MDS) International Prognostic Scoring System (IPSS) intermediate (Int)-2 or high risk (i.e., RAEB, RAEBt) or refractory anemia with severe pancytopenia or high risk cytogenetics; blasts must be < 10% in a representative bone marrow aspirate - Chronic myeloid leukemia excluding refractory blast crisis; to be eligible in first chronic phase (CP1) patient must have failed or be intolerant to tyrosine kinase inhibitor therapy - High dose TBI regimen: 10 to =< 45 years - Intermediate intensity regimen: 10 to =< 65 years - Patients 10 to =< 45 years:Lansky (< 16 years old) or Karnofsky (>= 16 years old) >= 70 or Eastern Cooperative Oncology Group (ECOG) 0-1 - Patients > 45 to =< 65 years: Karnofsky >= 70 or ECOG 0-1 and non-age adjusted comorbidity index =< 5 - Adults: Calculated creatinine clearance must be > 60 mL and serum creatinine =< 2 mg/dL - Children (< 18 years old): Calculated creatinine clearance must be > 60 mL/min - Total serum bilirubin must be < 3 mg/dL unless the elevation is thought to be due to Gilbert's disease or hemolysis - Transaminases must be < 3 x the upper limit of normal per reference values of treating institution - Carbon monoxide diffusing capability (DLCO) corrected >= 60% normal (may not be on supplemental oxygen) - For pediatric patients unable to perform pulmonary function tests, O2 saturation > 92% on room air - Left ventricular ejection fraction >= 50% OR - Shortening fraction > 26% - Ability of participant or legally authorized representative to understand and the willingness to sign a written informed consent form - DONOR: Minimum requirement: The cord blood (CB) unit must be matched at a minimum at 4/6 HLA-A, B antigens and DRB1 allele with the recipient; therefore, 0-2 mismatches at the A or B or DRB1 loci based on intermediate resolution at HLA-A, B and high resolution allele level typing at HLA- DRB1 are allowed - DONOR: Institutional guidelines for HLA-match may be followed as long as the minimum criteria for HLA-matching as above are met - DONOR: The CB unit selected for transplant must have a MINIMUM of 2.5 x 10^7 TNC/kg - DONOR: The minimum recommended CD34/kg cell dose is 1.7 x 10^5 CD34/kg - DONOR: A backup unit must be identified and reserved prior to the start of the treatment plan for possible infusion in the unlikely event of poor post-thaw viability of the primary CB unit. A suitable back up unit will be considered, as follows: - Must be matched at a minimum at 4/6 HLA-A, B, DRBl loci with the recipient. Therefore 0-2 mismatches at the A or B or DRBl loci based on intermediate resolution A, B antigen and DRBl allele typing for determination of HLA-match is allowed (Fred Hutch Protocol 2010). - Must contain a MINIMUM of 1.5 x 10^7 TNC/kg to ensure the same requirement we use for a standard double CBT per CB selection guideline (Fred Hutch Protocol 2010). Exclusion Criteria: - Uncontrolled viral or bacterial infection at the time of study enrollment - Active or recent (prior 6 month) invasive fungal infection unless cleared by infectious disease (ID) consult - History of human immunodeficiency virus (HIV) infection - Pregnant or breastfeeding - Prior allogeneic transplant - Central nervous system (CNS) leukemic involvement not clearing with intrathecal chemotherapy; diagnostic lumbar puncture is to be performed - < 30 kg

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Dilanubicel
Given IV
Drug:
Cyclophosphamide
Given IV
Fludarabine
Given IV
Thiotepa
Given IV
Radiation:
Total-Body Irradiation
Undergo TBI
Procedure:
Umbilical Cord Blood Transplantation
Given IV
Other:
Laboratory Biomarker Analysis
Correlative studies
Procedure:
Biospecimen Collection
Undergo blood sample collection
Bone Marrow Aspirate
Undergo bone marrow aspirate and biopsy
Bone Marrow Biopsy
Undergo bone marrow aspirate and biopsy
Multigated Acquisition Scan
Undergo MUGA
Electrocardiography
Undergo ECHO
Computed Tomography
Undergo CT

Locations

Country Name City State
United States Fred Hutch/University of Washington Cancer Consortium Seattle Washington

Sponsors (4)

Lead Sponsor Collaborator
Fred Hutchinson Cancer Center National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), Nohla Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of graft failure Primary graft failure/rejection as defined by no neutrophil recovery (regardless of donor chimerism) or autologous recovery (neutrophil recovery but < 10% donor chimerism in blood and bone marrow [BM]). Up to day 45 post-transplant
Secondary Time to neutrophil engraftment The day of neutrophil recovery will be the 1st day of 2 consecutive days of absolute neutrophil count at or above 500 after the 1st post-cord blood transplant nadir. Up to day 45 post-transplant
Secondary Time to platelet engraftment Measured by the number of participants with a platelet count > 20,000/ul without subsequent transfusions for 7 days Up to day 100 post-transplant
Secondary Incidence of adverse events Toxicities will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0. Up to day 100 post-transplant
Secondary Incidence of non-relapse mortality At day 100 post-transplant
Secondary Incidence of non-relapse mortality At 1 year post-transplant
Secondary Incidence and severity of acute graft versus host disease (GVHD) Assessed using the Acute GVHD Grading Scale (reference: Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-8). At day 100 post-transplant
Secondary Incidence and severity of chronic graft versus host disease (GVHD) Assessed using the Chronic GVHD Grading Scale (reference: Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and Staging Working Group report. Blood Marrow Transplant 2005; 11: 945-56). 1 year post-transplant
Secondary Incidence and severity of chronic graft versus host disease (GVHD) Assessed using the Chronic GVHD Grading Scale (reference: Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and Staging Working Group report. Blood Marrow Transplant 2005; 11: 945-56). Up to approximately 2 years post-transplant
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT05772000 - Clinical Significance of Occult Central Nervous System Localization
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT03114865 - A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance Phase 1/Phase 2
Not yet recruiting NCT06308588 - Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Phase 2
Recruiting NCT05579132 - A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia Phase 1/Phase 2
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Terminated NCT02231853 - Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2
Recruiting NCT06195891 - Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome Phase 1
Withdrawn NCT02815059 - Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone Phase 1
Completed NCT00390793 - Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. Phase 2
Recruiting NCT05866887 - Insomnia Prevention in Children With Acute Lymphoblastic Leukemia N/A
Completed NCT00026780 - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Not yet recruiting NCT06350994 - Early Assessment of Cardiac Function After Treatment With CAR-T Cells
Withdrawn NCT04282174 - CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies Phase 2
Not yet recruiting NCT04488237 - Vitamin D and Methotrexate Adverse Effects
Completed NCT02544438 - Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Phase 1/Phase 2